SRNE - Sorrento Therapeutics sciatica pain treatment meets primary endpoint in phase 3 trial

Sorrento Therapeutics (NASDAQ:SRNE) subsidiary Scilex's SP-102 (Semdex), a candidate for sciatica pain management, demonstrated rapid onset of pain relief in a late-stage trial. Four weeks after a single injection, patients taking SP-102 demonstrated a statistically significant mean improvement of -1.08 on the Numeric Pain Rating Scale. A secondary endpoint measuring degree of disability and estimating quality of life showed a 28% improvement at four weeks for those on SP-102 compared to baseline. Also, results showed that median time to open-label repeat injection was 99 days. The company said off-label injectable steroids typically provide relief for from less than a week to up to one month. SP-102 has Fast Track status from the U.S. FDA. Scilex previously said it intends to use the results to discuss with the FDA this year a licensure application and Breakthrough Designation Status.

For further details see:

Sorrento Therapeutics sciatica pain treatment meets primary endpoint in phase 3 trial